| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/21/2013 | CN102229588B Briarane type diterpenoid compounds with anti-tumor and antibacterial activities and application thereof |
| 08/21/2013 | CN102216302B Akt and p70 s6 kinase inhibitors |
| 08/21/2013 | CN102212159B Preparation method and application of solid-phase organic tin compound |
| 08/21/2013 | CN102198139B Pharmaceutical composition with antineoplastic effect, and application method thereof |
| 08/21/2013 | CN102178765B Preparation process for compound Chinese lobelia herb injection |
| 08/21/2013 | CN102172411B Nano complex particles with targeted MR (magnetic resonance) development and photothermal therapy performance and preparation method thereof |
| 08/21/2013 | CN102154325B Vaccine against human papillomavirus (HPV) as well as preparation method and application thereof |
| 08/21/2013 | CN102127056B Tubulin inhibitors |
| 08/21/2013 | CN102114000B Co-feeding lipid nano-delivery system for medicine carrying |
| 08/21/2013 | CN102106884B Medicinal composition having immunity-regulating function |
| 08/21/2013 | CN102091041B Novel nanoparticle of camptothecin drug and preparation method thereof |
| 08/21/2013 | CN102088982B Preparation of intermediates useful in the syntheis of 2'-cyano-2'-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosylcytosine |
| 08/21/2013 | CN102085378B Application of hfgl2 (Human Fibrinogen-like protein 2) inhibitor in preparation of medicaments for treating liver cancer |
| 08/21/2013 | CN102070618B Compound and crystals thereof |
| 08/21/2013 | CN102048693B Liposome having internal aqueous phases of benzenesulfonic acid derivatives |
| 08/21/2013 | CN102036963B Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| 08/21/2013 | CN102030800B Abies holophylla triterpenoid compound, extraction separation thereof and application thereof |
| 08/21/2013 | CN102026647B Pharmaceutical composition for treating or preventing cancer which induces dendritic cell-like differentiation of monocytes to increase anticancer immune activity |
| 08/21/2013 | CN101970670B Methods for inhibiting angiogenesis using egfl8 antagonists |
| 08/21/2013 | CN101941970B Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
| 08/21/2013 | CN101917993B Compounds for use in the treatment of cancer |
| 08/21/2013 | CN101874886B Method for measuring oleanolic acid content and ursolic acid content of Chinese medicinal composition |
| 08/21/2013 | CN101848892B Hydrobenzamide derivatives as inhibitors of HSP90 |
| 08/21/2013 | CN101817799B Cyanoacrylate compound and application thereof in pesticide and medicine |
| 08/21/2013 | CN101798343B Cancer suppressor gene coding protein sequence and fusion expression vector thereof |
| 08/21/2013 | CN101790517B Inhibitor of binding of s1p1 |
| 08/21/2013 | CN101616935B Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers |
| 08/21/2013 | CN101600714B Novel pyrindole kinase inhibitors |
| 08/21/2013 | CN101591322B Cyclin dependent kinases inhibitor scutellaria flavonoid organic amine derivatives, preparation method and application thereof |
| 08/21/2013 | CN101573382B Monoclonal antibodies and directed against the human anti-mullerian hormone type ii receptor (amhr-ii) |
| 08/20/2013 | US8513293 Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
| 08/20/2013 | US8513276 Imidazo[1,2-a]pyridine compounds for use in treating cancer |
| 08/20/2013 | US8513262 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| 08/20/2013 | US8513243 ABT-263 crystalline forms |
| 08/20/2013 | US8513237 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 08/20/2013 | US8513189 Albumin fusion proteins |
| 08/20/2013 | US8513185 Inhibition of TREM receptor signaling with peptide variants |
| 08/20/2013 | US8512969 Methods for analyzing a heparin sample |
| 08/20/2013 | US8512767 Pharmaceutical compositions |
| 08/20/2013 | US8512718 Pharmaceutical composition for topical application |
| 08/20/2013 | CA2751495C Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof |
| 08/20/2013 | CA2669800C Nerve elongation promoter and elongation inhibitor |
| 08/20/2013 | CA2641310C Igf-ir antagonists as adjuvants for treatment of prostate cancer |
| 08/20/2013 | CA2584170C Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases |
| 08/20/2013 | CA2559036C 9-substituted 8-oxoadenine compound |
| 08/20/2013 | CA2487824C Oncolytic viruses as phenotyping agents for neoplasms |
| 08/20/2013 | CA2452417C Compositions comprising the biologicially active peptide ysl |
| 08/20/2013 | CA2445349C Anti-cd40 monoclonal antibody |
| 08/15/2013 | WO2013120092A1 Methods for predicting response to cancer therapy |
| 08/15/2013 | WO2013120086A1 Inhibition of the glycine cleavage system for treatment of cancer |
| 08/15/2013 | WO2013119877A1 Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| 08/15/2013 | WO2013119825A1 Modulators of tousled kinase in cellular processes |
| 08/15/2013 | WO2013119809A1 Biomarkers for hematologic malignacies |
| 08/15/2013 | WO2013119774A1 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors |
| 08/15/2013 | WO2013119693A1 Emp2 regulates angiogenesis in cancer cells through induction of vegf |
| 08/15/2013 | WO2013118093A1 Therapeutic method of treatment for inhibiting tumor development using tamm-horsfall glycoprotein (thp) as immunostimulating drug and compositions |
| 08/15/2013 | WO2013118033A1 NOVEL BINDING SITE OF ΙΚΚ-β |
| 08/15/2013 | WO2013117683A1 New pediatric uses of cabazitaxel |
| 08/15/2013 | WO2013117649A1 Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
| 08/15/2013 | WO2013117647A1 Mica binding agents |
| 08/15/2013 | WO2013117646A1 Novel compound useful for the treatment of degenerative and inflammatory diseases |
| 08/15/2013 | WO2013117645A1 Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
| 08/15/2013 | WO2013117522A1 Aurora and flt3 kinases modulators |
| 08/15/2013 | WO2013117288A1 Tetrahydro-quinazolinone derivatives as tank and parp inhibitors |
| 08/15/2013 | WO2013117285A1 Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors |
| 08/15/2013 | WO2013116949A1 Glycosylated antitumor ether lipids as novel cancer stem cell cytotoxic agents |
| 08/15/2013 | WO2013116936A1 Medicament containing taraxacum plant root extract for treatment or prevention of cancer, and method for preparing same |
| 08/15/2013 | WO2013084148A3 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| 08/15/2013 | WO2013074816A3 Novel inhibitors of nox1 |
| 08/15/2013 | WO2013072766A3 Process for cabazitaxel and intermediates thereof |
| 08/15/2013 | WO2013064703A3 Fkbp subtype-specific rapamycin analogue for use in treatment of diseases |
| 08/15/2013 | WO2013061328A3 Methods of treating cancer |
| 08/15/2013 | WO2013030670A3 Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers |
| 08/15/2013 | WO2012156975A9 COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| 08/15/2013 | US20130211490 Everolimus Eluting Bioabsorbable Renal Artery Stent For Renal Cancer And Inflammatory Disorders |
| 08/15/2013 | US20130211368 Microfabricated nanopore device for sustained release of therapeutic agent |
| 08/15/2013 | US20130210875 Novel binding site of IKK-beta |
| 08/15/2013 | US20130210818 Novel Heterocyclic Compounds and Uses Thereof |
| 08/15/2013 | US20130210135 Recombinant vsv for the treatment of tumor cells |
| 08/15/2013 | US20130210116 Composition and methods for the diagnosis and treatment of tumor |
| 08/15/2013 | US20130209517 Cancer therapy |
| 08/15/2013 | US20130209516 Immunomodulatory compositions |
| 08/15/2013 | US20130209495 ErbB3 ANTIBODIES |
| 08/15/2013 | US20130209459 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 08/15/2013 | US20130209456 Subtypes of humanized antibody against interleukin-6 receptor |
| 08/15/2013 | US20130209443 Method for Treating Oncological Diseases |
| 08/15/2013 | CA2856403A1 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
| 08/14/2013 | EP2626418A1 Method for activating helper t cell |
| 08/14/2013 | EP2626414A1 Cancer stem cell mass and process for production thereof |
| 08/14/2013 | EP2626353A1 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| 08/14/2013 | EP2626351A1 Agent for inhibiting expression of lipid metabolism related mrna |
| 08/14/2013 | EP2626083A1 Multi-arm polymer prodrugs |
| 08/14/2013 | EP2626067A1 Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| 08/14/2013 | EP2626066A1 Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors |
| 08/14/2013 | EP2625187A1 Phosphoramidite derivatives of gemcitabine for use in the treatment cancer |
| 08/14/2013 | EP2625176A2 Substituted pyridazine carboxamide compounds |
| 08/14/2013 | EP2625175A1 Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |
| 08/14/2013 | EP2625173A2 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
| 08/14/2013 | EP2625168A1 Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides |
| 08/14/2013 | EP2624858A1 Use of a phosphopeptide able to block her3/p85 interaction for the treatment of her2 hyper-expressing tumours |